🇺🇸 FDA
Patent

US 11572359

PARP/PI3K double-target inhibit containing pyridopyrimidine structure

granted A61KA61K31/5377A61P

Quick answer

US patent 11572359 (PARP/PI3K double-target inhibit containing pyridopyrimidine structure) held by CHINA PHARMACEUTICAL UNIVERSITY expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CHINA PHARMACEUTICAL UNIVERSITY
Grant date
Tue Feb 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K31/5377, A61P, A61P35/00